Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

BIXT Relative to the S&P 500

BIXT Relative to the Sector

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Bioxytran Inc. (OTCMKT:BIXT) seasonal charts above shows that a Buy Date of January 24 and a Sell Date of April 15 has resulted in a geometric average return of 37.63% above the benchmark rate of the S&P 500 Total Return Index over the past 15 years. This seasonal timeframe has shown positive results compared to the benchmark in 12 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 15 years by an average of 83.51% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. Its product pipeline includes BXT-25, a drug designed to oxygenate ischemic (reduced blood flow) regions in the brain that suffered from hypoxia during a brain stroke, and BXT-252, which treats chronic wounds resulting from ischemia caused by occlusion of capillaries. The company was founded on June 9, 2008 and is headquartered in Needham, MA.

To download BIXT seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: BIXT